Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Melanoma | D008545 | — | — | 2 | 4 | 1 | — | — | 5 |
Uveal neoplasms | D014604 | EFO_1001230 | — | 2 | 4 | 1 | — | — | 5 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Colorectal neoplasms | D015179 | — | — | 1 | 1 | — | — | — | 1 |
Neoplasms | D009369 | — | C80 | 1 | 1 | — | — | — | 1 |
Drug common name | Darovasertib |
INN | darovasertib |
Description | Darovasertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target protein kinase C alpha type and protein kinase C theta type. |
Classification | Small molecule |
Drug class | serine/threonine kinase inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC1(N)CCN(c2cccnc2NC(=O)c2nc(-c3ncccc3C(F)(F)F)cnc2N)CC1 |
PDB | — |
CAS-ID | 1874276-76-2 |
RxCUI | — |
ChEMBL ID | CHEMBL3982723 |
ChEBI ID | — |
PubChem CID | 118873253 |
DrugBank | DB16059 |
UNII ID | E0YF0M8O09 (ChemIDplus, GSRS) |